ARMP241115C5000
- 0.25
- 0.000.00%
Armata Pharmaceuticals Newsroom
Armata Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $7
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $7
Armata Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Ladenburg Thalmann Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Armata Pharmaceuticals Amid Positive Earnings and Promising Clinical Progress
Analysts' Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Armata Pharmaceuticals (ARMP)
Armata Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Armata Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Denali Therapeutics (DNLI) and Armata Pharmaceuticals (ARMP)
Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy Development
Armata Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Maintains $7 Price Target
Buy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic Growth
Robust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals' Buy Rating
Ladenburg Thalmann & Co. Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)